News
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.
New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.
Pharmaceutical giant Eli Lilly said last week that it will raise the U.K. list price of its weight-loss treatment Mounjaro by ...
The UK list price of the weight loss drug could nearly triple, but which patients will bear the brunt of the internationally “aligned” cost? Kate Bowie reports In May the Trump administration demanded ...
This is an audio transcript of the FT News Briefing podcast episode: ‘What to expect from Jay Powell’s Jackson Hole speech’ Sonja Hutson Good morning from the Financial Times. Today is Wednesday, ...
A Shropshire GP has said many patients are worried about having to stop their weight loss journey as the cost of Mounjaro is ...
Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...
Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...
23h
Investor's Business Daily on MSNViking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill
Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results